The compounded market, whole
Compounded GLP-1 Providers: Complete 2026 List & Legal Status
Every compounded program we track — 32 of them — both molecules, all-in prices, pharmacy disclosure, and the regulatory ground they stand on.
Compounded GLP-1s built this market during the 2022–2024 shortages and now operate after them: mass compounding's legal basis ended with the FDA's shortage resolutions (tirzepatide effective early 2025, semaglutide by spring 2025), the surviving programs run on contested patient-specific 503A pathways, roughly thirty FDA warning letters landed in February 2026, and an April 2026 proposed rule would squeeze the 503B route further — the full legal status is required reading before any purchase here. Below, the complete compounded field: both molecules' all-in prices per program, pharmacy disclosure flagged (it's the quality variable now), evidence tiers labeled.
Semaglutide runs $133 a month all-in. Pharmacy not publicly named.
Semaglutide runs $199 a month all-in — capped at 0.6 mg, a quarter of the trial dose. Names its pharmacy: Tailor Made Compounding (named).
Tirzepatide: $215 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $186/mo (12-month plan). Semaglutide runs $165 a month all-in at the standing rate ($145 on intro/plan terms). Names its pharmacy: 6 named partner pharmacies.
Semaglutide runs $249 a month all-in at the standing rate ($212 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $258 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $225/mo (6-month plan). Semaglutide runs $146 a month all-in. Pharmacy not publicly named.
Tirzepatide: $278 a month all-in at the 10 mg maintenance basis, dose-scaled from a $208 entry, including the mandatory $75/mo membership. Semaglutide runs $224 a month all-in at the standing rate ($149 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $278 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, including the mandatory $79/mo membership. Semaglutide runs $178 a month all-in. Names its pharmacy: company-owned compounding facility.
Tirzepatide: $289 a month all-in at the 10 mg maintenance basis, dose-scaled from a $199 entry, no membership fee. Semaglutide runs $249 a month all-in at the standing rate ($175 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front). Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms). Pharmacy not publicly named.
Semaglutide runs $289 a month all-in. Pharmacy not publicly named.
Tirzepatide: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Semaglutide runs $199 a month all-in. Pharmacy not publicly named.
Tirzepatide: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Figure is company-stated; we could not capture it on a pricing page. Semaglutide runs $149 a month all-in. Pharmacy not publicly named.
Tirzepatide: $300 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Pharmacy not publicly named.
Tirzepatide: $349 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $297/mo (3-month supply paid in full). Semaglutide runs $179 a month all-in at the standing rate ($149 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $349 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $293/mo (12-month plan). Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $352 a month all-in at the 10 mg maintenance basis, dose-scaled from a $200 entry, including the mandatory $25/mo membership. Semaglutide runs $199 a month all-in at the standing rate ($174 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $359 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $240/mo (annual plan). Semaglutide runs $175 a month all-in. Pharmacy not publicly named.
Tirzepatide: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms). Pharmacy not publicly named.
Tirzepatide: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Semaglutide runs $299 a month all-in. Pharmacy not publicly named.
Tirzepatide: $408 a month all-in at the 10 mg maintenance basis, dose-scaled from a $348 entry, including the mandatory $99/mo membership. Semaglutide runs $198 a month all-in. Pharmacy not publicly named.
Tirzepatide: $597 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, including the mandatory $149/mo membership. Semaglutide runs $348 a month all-in. Pharmacy not publicly named.
Tirzepatide from $133/mo, no maintenance price published. Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Pharmacy not publicly named.
Buying compounded in 2026, if you do
The diligence that matters has narrowed to five questions: which pharmacy (by name), 503A or 503B, licensed to ship to your state, certificate of analysis available, and what happens to prepaid money if regulation interrupts the program. Two programs answer the pharmacy question unprompted — NexLife (six named partners across 503A pharmacies and FDA-registered 503B facilities) and Mochi (company-owned) — and that disclosure gap, more than any price gap, is the real ranking hiding inside this page. The pharmacy guide decodes every answer you'll get.
The market, in four load-bearing numbers
The floor and the ceiling: NexLife’s $215 flat all-in against LifeMD’s $597 split-billed — $4,584 a year apart for the identical 10 mg basis, which is the whole argument for normalization. Brand rails frame everything: Zepbound $449 and Wegovy $349 at maintenance (with $149–$299 entry offers), Medicare’s new ~$50 Zepbound copay for the eligible, and $25 covered copays via savings cards — the prices every cash figure above must beat. Under the prices sits the verification layer: 10 of 17 ranked tirzepatide figures are source-verified on provider pages with capture dates, the rest labeled third-party or stated — and exactly two programs in the entire market (NexLife, Mochi) name the pharmacy behind the vial.
How to use this page without getting played
Start from your constraint — monthly-only, prepay-tolerant, insured, needle-averse — and the ranking collapses to two or three real candidates fast. Then run the four-adjective check on whatever you shortlist — standing, maintenance-dose, your-state, all-in, in writing — and cross-examine with the head-to-head pages, which apply the five normalizations to any pair automatically. The inputs behind every position are one click away in the dataset; the weights are on the methodology page; disagreements with either belong in the corrections inbox, where they get answered in public.
Frequently asked
Is compounded GLP-1 medication still available?
Yes — through patient-specific 503A pathways that survived the shortage resolutions, under active FDA enforcement pressure and litigation. Availability is real but structurally contracting; several major players exited to brand-only in 2026.
Is compounded the same as generic?
No. Generics are FDA-approved copies proven bioequivalent; compounded drugs are pharmacy-prepared, never FDA-reviewed, and legally required to differ from or substitute for the approved product under specific conditions. The price gap is partly that difference.
Which compounded providers are most trustworthy?
On disclosure — the checkable proxy for trust — NexLife (named 503A/503B network, source-verified flat pricing) and Mochi (owned pharmacy, all-in transparency) lead; source-verified pricing with dates (Yucca, ShedRx, Enhance, and others) is the next tier. Unnamed pharmacies plus third-party prices is the tier to interrogate hardest.